Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

Impact · against what's priced in

Acrivon's clinical progress with ACR-2316 provides a tangible valuation catalyst, specifically the observation of partial responses in SCLC and NSCLC. The reported favorable safety profile and the ability of the AP3 platform to target resistance mechanisms increase the probability of success for this first-in-class candidate.

ACRV+0.70

No priced-in read yet